Allen Lee Cohn

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu, Richard S. Finn, Julien Edeline et al. · The Lancet Oncology · 2018 · 2.5K citations

Medicine, Oncology, Pharmacology +11

Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set

Eric A. Klein, Donald Richards, Allen Lee Cohn et al. · Annals of Oncology · 2021 · 963 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

Josep Tabernero, Takayuki Yoshino, Allen Lee Cohn et al. · The Lancet Oncology · 2015 · 955 citations

Medicine, Oncology, Pharmacotherapy +12

A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer

J. Randolph Hecht, Edith P. Mitchell, Tarek Chidiac et al. · Journal of Clinical Oncology · 2008 · 852 citations · Full text

Medicine, Oncology, Pharmacology +15

Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study

Howard S. Höchster, Lowell L. Hart, Ramesh K. Ramanathan et al. · Journal of Clinical Oncology · 2008 · 623 citations

Medicine, Oncology, Pharmacotherapy +13